Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review
- PMID: 33292364
- PMCID: PMC7670699
- DOI: 10.1186/s13027-020-00335-2
Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review
Abstract
Background: Cervical cancer screening is slowly transitioning from Pappanicolaou cytologic screening to primary Visual Inspection with Acetic Acid (VIA) or HPV testing as an effort to enhance early detection and treatment. However, an effective triage tests needed to decide who among the VIA or HPV positive women should receive further diagnostic evaluation to avoid unnecessary colposcopy referrals is still lacking. Evidence from experimental studies have shown potential usefulness of Squamous Cell Carcinoma Antigen (SCC Ag), Macrophage Colony Stimulating Factor (M-CSF), Vascular Endothelial Growth Factor (VEGF), MicroRNA, p16INKa / ki-67, HPV E6/E7/mRNA, and DNA methylation biomarkers in detecting premalignant cervical neoplasia. Given the variation in performance, and scanty review studies in this field, this systematic review described the diagnostic performance of some selected assays to detect high-grade cervical intraepithelial neoplasia (CIN2+) with histology as gold standard.
Methods: We systematically searched articles published in English between 2012 and 2020 using key words from PubMed/Medline and SCOPUS with two reviewers assessing study eligibility, and risk of bias. We performed a descriptive presentation of the performance of each of the selected assays for the detection of CIN2 + .
Results: Out of 298 citations retrieved, 58 articles were included. Participants with cervical histology yielded CIN2+ proportion range of 13.7-88.4%. The diagnostic performance of the assays to detect CIN2+ was; 1) SCC-Ag: range sensitivity of 78.6-81.2%, specificity 74-100%. 2) M-CSF: sensitivity of 68-87.7%, specificity 64.7-94% 3) VEGF: sensitivity of 56-83.5%, specificity 74.6-96%. 4) MicroRNA: sensitivity of 52.9-67.3%, specificity 76.4-94.4%. 5) p16INKa / ki-67: sensitivity of 50-100%, specificity 39-90.4%. 6) HPV E6/E7/mRNA: sensitivity of 65-100%, specificity 42.7-90.2%, and 7) DNA methylation: sensitivity of 59.7-92.9%, specificity 67-98%.
Conclusion: Overall, the reported test performance and the receiving operating characteristics curves implies that implementation of p16ink4a/ki-67 assay as a triage for HPV positive women to be used at one visit with subsequent cryotherapy treatment is feasible. For the rest of assays, more robust clinical translation studies with larger consecutive cohorts of women participants is recommended.
Keywords: DNA methylation; HPV E6/E7/mRNA; MicroRNA; SCC-Ag. Performance; p16INKa / ki-67.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
HPV E6/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review.Infect Agent Cancer. 2020 Feb 7;15:9. doi: 10.1186/s13027-020-0278-x. eCollection 2020. Infect Agent Cancer. 2020. PMID: 32047531 Free PMC article. Review.
-
Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.Int J Cancer. 2019 Jan 1;144(1):34-42. doi: 10.1002/ijc.31633. Epub 2018 Oct 26. Int J Cancer. 2019. PMID: 29943809
-
Performance of the HPV-16 L1 methylation assay and HPV E6/E7 mRNA test for the detection of squamous intraepithelial lesions in cervical cytological samples.J Virol Methods. 2015 Nov;224:35-41. doi: 10.1016/j.jviromet.2015.08.008. Epub 2015 Aug 20. J Virol Methods. 2015. PMID: 26297960
-
Diagnostic value of HPV E6/E7 mRNA in screening for cervical intraepithelial neoplasia grade 2 or worse: A systematic review and meta‑analysis.Oncol Lett. 2024 Mar 26;27(5):231. doi: 10.3892/ol.2024.14364. eCollection 2024 May. Oncol Lett. 2024. PMID: 38586199 Free PMC article.
-
Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Vaccine. 2008. PMID: 18847555 Review.
Cited by
-
The Evolving Landscape of Cervical Cancer: Breakthroughs in Screening and Therapy Through Integrating Biotechnology and Artificial Intelligence.Mol Biotechnol. 2025 Mar;67(3):925-941. doi: 10.1007/s12033-024-01124-7. Epub 2024 Apr 4. Mol Biotechnol. 2025. PMID: 38573545 Review.
-
Exploration of biomarkers for the diagnosis, treatment and prognosis of cervical cancer: a review.Discov Oncol. 2022 Sep 24;13(1):91. doi: 10.1007/s12672-022-00551-9. Discov Oncol. 2022. PMID: 36152065 Free PMC article. Review.
-
The role of co-infections and hormonal contraceptives in cervical intraepithelial neoplasia prevalence among women referred to a tertiary hospital in Western Kenya.Infect Agent Cancer. 2025 Feb 24;20(1):11. doi: 10.1186/s13027-024-00620-4. Infect Agent Cancer. 2025. PMID: 39994762 Free PMC article.
-
Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.Gynecol Oncol. 2024 Nov;190:160-166. doi: 10.1016/j.ygyno.2024.08.006. Epub 2024 Aug 27. Gynecol Oncol. 2024. PMID: 39197415
-
LASSO and Bioinformatics Analysis in the Identification of Key Genes for Prognostic Genes of Gynecologic Cancer.J Pers Med. 2021 Nov 11;11(11):1177. doi: 10.3390/jpm11111177. J Pers Med. 2021. PMID: 34834529 Free PMC article.
References
-
- Sidorkiewicz I, Zbucka-Krętowska M, Zaręba K, Lubowicka E, Zajkowska M, Szmitkowski M, Gacuta E, Ławicki S. Plasma levels of M-CSF and VEGF in laboratory diagnostics and differentiation of selected histological types of cervical cancers. BMC Cancer. 2019;19:398. doi: 10.1186/s12885-019-5558-8. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials